FDA Accepts Supplement for Vyvanse (NDA 208510) from Takeda
The FDA has accepted a supplemental application for Vyvanse (lisdexamfetamine dimesylate) from Takeda Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for Vyvanse with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has accepted a supplemental application for VYVANSE, an ADHD treatment, submitted by Takeda.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.